One of the easiest mistakes in biosimilar strategy is assuming the formulary decision is the hard part. More often, the challenge starts after the policy is set. Pharmacy leaders know how to do the biosimilar strategy work upfront. They evaluate the market, build coverage rules, update formularies, and negotiate around cost. But none of that … Continue reading Formulary Change Is Only the Start: Transition Determines Biosimilar Success